<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044793</url>
  </required_header>
  <id_info>
    <org_study_id>07408</org_study_id>
    <nct_id>NCT05044793</nct_id>
  </id_info>
  <brief_title>An Observational Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System</brief_title>
  <official_title>An Observational Multicenter Clinical Study To Assess The Long-Term Safety And Effectiveness Of The OMNI® Surgical System In Combination With Cataract Surgery In Eyes With Open Angle Glaucoma (GEMINI 2.0)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sight Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sight Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and effectiveness of the OMNI®&#xD;
      Surgical System in subjects who were treated under protocol #06213&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intraocular pressure (IOP)</measure>
    <time_frame>24months</time_frame>
    <description>Change in unmedicated mean diurnal IOP (DIOP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in number of medications</measure>
    <time_frame>24months</time_frame>
    <description>Change in the number of ocular hypotensive medications</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Number of Subjects Enrolled</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMNI® Surgical System</intervention_name>
    <description>The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.</description>
    <arm_group_label>Number of Subjects Enrolled</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who received treatment and completed Protocol #06213&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Participated in, received treatment, and completed Protocol #06213&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic disease that, in the opinion of the Investigator, would put the subject's&#xD;
             health at risk and/or prevent completion of required study visits&#xD;
&#xD;
          -  Ocular pathology which, in the Investigator's judgment, would either place the subject&#xD;
             at increased risk of complications, contraindicate washout, place the subject at risk&#xD;
             of significant vision loss during the study period (e.g., wet age macular degeneration&#xD;
             (AMD), corneal edema, Fuch's dystrophy, active intraocular infection or inflammation&#xD;
             within 30 days prior to Screening Visit, etc.), or interfere with compliance to&#xD;
             elements of the study protocol (e.g., returning to Investigator's office for follow-up&#xD;
             visits)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kavita Dhamdhere, MD</last_name>
    <phone>877-266-1144</phone>
    <email>kdhamdhere@sightsciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grene Vision Group</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>62708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Eye Surgeons</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern Ophthalmics</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

